Summary by Futu AI
Conduit Pharmaceuticals Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the trading symbols CDT for its common stock and CDTTW for its redeemable warrants, has announced the scheduling of its 2024 Annual Meeting of Stockholders for October 2, 2024. The company, which is classified as an emerging growth company, has also set August 20, 2024, as the record date for determining stockholders entitled to notice of, and to vote at, the Annual Meeting. This announcement comes after the company did not hold an annual meeting in 2023. Consequently, Conduit Pharmaceuticals is informing shareholders of the July 11, 2024 deadline for the submission of qualified stockholder proposals or director nominations to be included in the proxy statement for the upcoming Annual Meeting. The proposals and nominations must adhere to the rules and regulations of the Securities and Exchange Commission, including Rule 14a-8 under the Exchange Act, as well as the company's bylaws. The report, signed by CEO Dr. David Tapolczay, was filed with the SEC on July 1, 2024.
